Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA

Pat Gulhati, Yekaterina Y. Zaytseva, Joseph D. Valentino, Payton D. Stevens, Ji Tae Kim, Takehiko Sasazuki, Senji Shirasawa, Eun Y. Lee, Heidi L. Weiss, Jianli Dong, Tianyan Gao, B. Mark Evers

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling is associated with tumorigenesis and metastasis of colorectal cancer (CRC). The mammalian target of rapamycin (mTOR) kinase, a downstream effector of PI3K/Akt signaling, regulates tumorigenesis and metastasis of CRCs, indicating that mTOR inhibition may have therapeutic potential. Notwithstanding, many cancers, including CRC, demonstrate resistance to the antitumorigenic effects of rapamycin. In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance. Combination with the multikinase inhibitor, sorafenib, abrogates rapamycin-induced activation of PI3K/Akt and Ras-MAPK signaling pathways. Combination of rapamycin with sorafenib synergistically inhibits proliferation of CRC cells. CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib. Combination with sorafenib enhances therapeutic efficacy of rapamycin on induction of apoptosis and inhibition of cell-cycle progression, migration and invasion of CRCs. We demonstrate efficacy and safety of concomitant treatment with rapamycin and sorafenib at inhibiting growth of xenografts from CRC cells with coexistent mutations in KRAS and PIK3CA. The efficacy and tolerability of combined treatment with rapamycin and sorafenib provides rationale for use in treating CRC patients, particularly those with tumors harboring coexistent KRAS and PIK3CA mutations. Abbreviations: CIcombination index. CRCcolorectal cancer. IHCimmunohistochemistry. MAPKmitogen activated protein kinase. mTORmammalian target of rapamycin. PI3Kphosphatidylinositol 3-kinase.

Original languageEnglish (US)
Pages (from-to)1782-1790
Number of pages9
JournalCarcinogenesis
Volume33
Issue number9
DOIs
StatePublished - Sep 1 2012

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA'. Together they form a unique fingerprint.

  • Cite this

    Gulhati, P., Zaytseva, Y. Y., Valentino, J. D., Stevens, P. D., Kim, J. T., Sasazuki, T., Shirasawa, S., Lee, E. Y., Weiss, H. L., Dong, J., Gao, T., & Mark Evers, B. (2012). Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis, 33(9), 1782-1790. https://doi.org/10.1093/carcin/bgs203